Buy Crypto
Pay with
USD
USD
Buy & Sell
Hot
Supports Visa, Mastercard, SEPA & more
P2P
0 Fees
Flexible trading, zero fees
Gate Card
Use your crypto for payments worldwide
Markets
Trade
Basic
Advanced
Futures
Futures
Access hundreds of perpetual contracts
CFD
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
U.S. Stocks
CFD
U.S. stock CFD derivatives
Futures
High leverage, 24/7 trading
Tokenized Stocks
Backed by real stock assets
GUSD
Mint GUSD for Treasury RWA yields
Earn
Launch
CandyDrop
tag
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Investment
Square
Square
Post, share, and explore crypto trends
Live
moments live
Live crypto market analysis
Chat
Chat with crypto traders
News
What is happening in crypto
flower_head
More
Promotions
AI
Others
TradFi
Rewards
Square
Latest
Hot
News
Profile

Driving innovation in drug development, artificial intelligence virtual screening platform launched in Tianjin

MarsBitNews
Mars Finance News, May 30 — The AI virtual screening platform for ultra-large-scale drug discovery — GalaxyVS — was officially launched today.
The platform relies on the new generation Tianhe supercomputing system, targeting nearly one trillion synthesizable compound spaces, and has built an end-to-end technical system covering molecular characterization, vector retrieval, diversity control, affinity re-ranking, and large-scale task scheduling, providing a high-efficiency, high-precision, scalable new foundational platform for innovative drug development.
(Xinhua)
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • 6
  • 2
  • Share
Comment
Add a comment
Add a comment
MistBlueLily
· 3h ago
End-to-end technology system sounds very complete, but what about the implementation cost? Can small and medium-sized pharmaceutical companies afford it?
View OriginalReply0
MosaicButterfly
· 3h ago
The virtual screening platform is heating up; GalaxyVS and DeepMind's AlphaFold—who's more impressive?
View OriginalReply0
OnchainComplainer
· 3h ago
Improving the efficiency of new drug development is a great benefit for national healthcare insurance, but how can data security and intellectual property rights be protected?
View OriginalReply0
ShatteredGlaze
· 3h ago
Molecular characterization and re-ranking based on affinity, covering the entire chain—this is what AI-driven drug discovery should look like.
View OriginalReply0
MinersUnderTheNeonBridge
· 4h ago
Super-large scale + synthesizable, finally no longer just a concept in papers, waiting for an open-source or collaboration announcement.
View OriginalReply0
StopMessingAroundWithGasFees.
· 4h ago
Xinhua News Agency endorsement, full display, looking forward to actual cases
View OriginalReply0

  • Pinned

Sitemap